Evercore ISI Adjusts Price Target on Boston Scientific to $52 From $65
Evercore ISI reduced its price target for Boston Scientific from $65 to $52. The company also announced management changes effective January 1, 2027. Boston Scientific's stock is currently trading at $42.16, down 3.44% year-to-date.
How this was made
The 30-second read
Why it matters
The target reduction signals a shift in valuation expectations, which could trigger short‑selling or profit‑taking.
Market read
Analyst target cuts are a common catalyst for short‑term price moves; traders should monitor BSX for potential downside.
What to watch
Potential upcoming product launches or regulatory approvals not reflected in the target.
Background
Evercore ISI regularly updates price targets based on its valuation models and earnings expectations.
Ticker impact
Evercore ISI cut its price target for Boston Scientific to $52 from $65, indicating a bearish outlook.
likely pressure as the market prices in the lower target
Target reduction is a fresh analyst action that can prompt sell‑side trading.
Market effects
May weigh on the broader med‑tech sector as analysts reassess valuations.
Limited to U.S. markets where Boston Scientific trades.
Minimal global impact beyond sector peers.
Counterpoint
Some investors may view the cut as an over‑reaction and see buying opportunity.
Key entities
- companyBoston Scientific
Medical device manufacturer (ticker BSX).
- analystEvercore ISI
Equity research firm providing price targets.
